Kamel Izeradjene
Impact in
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Immunology top 10%
- Immune cells in cancer
Papers in
- Oncology 11
- Cancer-related Molecular Pathways 4
- Pancreatic and Hepatic Oncology Research 3
- HER2/EGFR in Cancer Research 2
-
- Cell death mechanisms and regulation 7
- RNA Interference and Gene Delivery 3
- Co-authors
- Jean‐Pierre Revillard (2 shared papers)Janet A. Houghton (7 shared papers)Sunil R. Hingorani (4 shared papers)Laurent Genestier (2 shared papers)Laurence Quéméneur (2 shared papers)Romain Paillot (1 shared paper)Markus A. Carlson (2 shared papers)David M. Tillman (3 shared papers)
- Journals
- Cancer Research (2 papers)Journal of Clinical Oncology (1 paper)Clinical Cancer Research (1 paper)The FASEB Journal (1 paper)International Immunology (1 paper)
- Partner nations
- United StatesFranceHungary
In The Last Decade
Kamel Izeradjene
15 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 99
- Oncology 642
- Immunology 302
- Cancer Research 198
- Molecular Biology 672
- Hematology 84
Countries citing papers authored by Kamel Izeradjene
This map shows the geographic impact of Kamel Izeradjene's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamel Izeradjene with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamel Izeradjene more than expected).
Fields of papers citing papers by Kamel Izeradjene
This network shows the impact of papers produced by Kamel Izeradjene. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamel Izeradjene. The network helps show where Kamel Izeradjene may publish in the future.
Co-authors
The 25 scholars most cited alongside Kamel Izeradjene, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 332 | |
| 2 | 2007 | 273 | |
| 3 | 2014 | 258 | |
| 4 | 2015 | 156 | |
| 5 | 2005 | 91 | |
| 6 | Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. | 2003 | 90 |
| 7 | 2005 | 73 | |
| 8 | 2004 | 50 | |
| 9 | 2004 | 40 | |
| 10 | 2001 | 33 | |
| 11 | 2006 | 31 | |
| 12 | 2003 | 29 | |
| 13 | 2001 | 15 | |
| 14 | 2001 | 10 | |
| 15 | 2007 | 9 | |
| 16 | 2025 | 0 | |
| 17 | 2020 | 0 |
About Kamel Izeradjene
Kamel Izeradjene is a scholar working on Oncology, Molecular Biology, Immunology, Cancer Research and Epidemiology, having authored 17 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (7 papers), NF-κB Signaling Pathways (5 papers), Cancer-related Molecular Pathways (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), RNA Interference and Gene Delivery (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Immune Cell Function and Interaction (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Oncology (642 citations), Immunology (302 citations), Cancer Research (198 citations), Molecular Biology (672 citations) and Hematology (84 citations). Kamel Izeradjene has collaborated with scholars based in United States, France and Hungary. Frequent co-authors include Jean‐Pierre Revillard, Janet A. Houghton, Sunil R. Hingorani, Laurent Genestier, Laurence Quéméneur, Romain Paillot, Markus A. Carlson, David M. Tillman, Ralph H. Hruban and Carlos Cuevas. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research, The FASEB Journal and International Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.